Metabonomics Study of Ginseng Glycoproteins on Improving Sleep Quality in Mice.
Study Design
- Tipo de estudio
- animal_study
- Tamaño de muestra
- 20
- Intervención
- Metabonomics Study of Ginseng Glycoproteins on Improving Sleep Quality in Mice. 60 mg/kg ginseng glycoproteins (GPr) i.p.
- Comparador
- Placebo
- Dirección del efecto
- Positive
- Riesgo de sesgo
- High
Abstract
The changes of brain metabolism in mice after injection of ginseng glycoproteins (GPr) were analyzed by gas chromatography mass spectrometry- (GC/MS-) based metabolomics platform. The relationship between sedative and hypnotic effects of ginseng glycoproteins and brain metabolism was discussed. Referring to pentobarbital sodium subthreshold test, we randomly divided 20 mice into two groups: control and ginseng glycoproteins group. The mice from the control group were treated with normal saline by i.p and GPr group were treated with 60 mg/kg of GPr by i.p. The results indicated that GPr could significantly improve the sleep quality of mice. Through multivariate statistical analysis, we found that there were 23 differential metabolites in whole brain tissues between the control group and the GPr group. The pathway analysis exhibited that GPr may be involved in the regulation of the pathway including purine metabolism, nicotinate and nicotinamide metabolism, glycine, serine and threonine metabolism, arginine and proline metabolism, alanine, aspartate and glutamate metabolism, and steroid hormone biosynthesis. This work is helpful to understand the biochemical mechanism of GPr on promoting sleep and lay a foundation for further development of drugs for insomnia.
Full Text
Figures
Figure 1
Experimental design and sleep testing protocol for evaluating ginseng glycoproteins' sedative and hypnotic effects in mice. The pentobarbital sodium subthreshold test setup illustrates how sleep latency and duration were measured across treatment groups.
diagram
Figure 2
GC/MS-based metabolomic profiling of brain tissue from mice treated with ginseng glycoproteins versus controls. Principal component analysis or similar multivariate visualization reveals distinct metabolic clustering between the two groups.
chart
Figure 3
Differential brain metabolites identified between ginseng glycoprotein-treated and control mice using GC/MS metabolomics. Significant changes in amino acids, neurotransmitter precursors, and energy metabolites suggest multiple pathways are influenced.
chart
Figure 4
Metabolic pathway mapping of the significantly altered brain metabolites following ginseng glycoprotein treatment in mice. Pathways related to neurotransmitter synthesis, energy metabolism, and amino acid processing are highlighted.
diagram
Figure 5
Correlation network or heatmap showing relationships among altered brain metabolites in ginseng glycoprotein-treated mice. The analysis links metabolomic changes to the observed improvements in sleep parameters.
chartTables
Table 1
| Group | Sleep latency | Sleep time |
|---|---|---|
| Control | 533.2 ± 110.3 | 3166.1 ± 1325.2 |
| Ginseng glycoproteins | 308.6 ± 68.3 | 5445.5 ± 1415.2 |
Table 2
| Metabolites | SV | Control | GPr | VIP | P-VALUE | Trend |
|---|---|---|---|---|---|---|
| Inosine | 933 | 230 | 0.26883496 | 0.474806953 | 1.403129 |
|
| Aspartic acid 1 | 930 | 232 | 1.394412343 | 2.302817461 | 1.95754 |
|
| 3-Hydroxybutyric acid | 896 | 147 | 0.03413712 | 0.057421069 | 1.790805 |
|
| Phosphate | 826 | 373 | 9.58593E-07 | 0.003834269 | 2.238158 |
|
| 2-Monopalmitin | 761 | 218 | 0.000916024 | 0.007080175 | 1.305231 |
|
| 2-Monoolein | 725 | 103 | 0.007766589 | 0.0193021 | 1.57449 |
|
| cis-Gondoic acid | 697 | 175 | 9.58593E-07 | 0.013856645 | 2.387345 |
|
| Inosine 5′-monophosphate | 687 | 315 | 9.58593E-07 | 0.001733039 | 2.083737 |
|
| Nicotinic acid | 586 | 180 | 0.001234995 | 0.004313206 | 2.41329 |
|
| Dihydroxyacetone | 558 | 163 | 0.000153415 | 0.000706533 | 1.70357 |
|
| Linoleic acid methyl ester | 542 | 86 | 0.022472983 | 0.055198241 | 1.340144 |
|
| m-Cresol | 534 | 165 | 0.001404886 | 0.002949009 | 1.930035 |
|
| Mannitol | 517 | 319 | 0.001031488 | 0.002153881 | 1.063901 |
|
| Cortisone | 499 | 103 | 9.58593E-07 | 0.006679172 | 1.942847 |
|
| 2-Hydroxyvaleric acid | 446 | 102 | 0.000877641 | 0.001813946 | 1.95695 |
|
| Phosphoglycolic acid | 425 | 299 | 0.005146486 | 0.013489075 | 1.927157 |
|
| Phytanic acid | 357 | 159 | 0.004245082 | 0.001927866 | 1.541776 |
|
| 3,4-Dihydroxypyridine | 337 | 256 | 0.003866274 | 0.007287569 | 1.81441 |
|
| 3,5-Dihydroxyphenylglycine 1 | 316 | 283 | 0.003695243 | 0.010222014 | 1.836686 |
|
| Hexadecane | 279 | 199 | 0.017033444 | 0.030171359 | 2.100437 |
|
| Creatine degr | 276 | 316 | 0.000734181 | 0.001345046 | 1.841828 |
|
| 4-Hydroxymethyl-3-methoxyphenoxyacetic acid | 241 | 366 | 0.001093006 | 0.000727609 | 1.032588 |
|
| trans-2-Hydroxycinnamic acid | 226 | 219 | 0.00088091 | 0.001805154 | 1.16949 |
|
Table 3
| pathway | Differential metabolites in the pathway |
|---|---|
| Carbon metabolism | Aspartic acid 1; Dihydroxyacetone; Phosphoglycolic acid |
| Purine metabolism | Inosine; Inosine 5′-monophosphate |
| Glycine, serine and threonine metabolism | Aspartic acid 1;Creatine |
| Nicotinate and nicotinamide metabolism | Aspartic acid 1;Nicotinic acid |
| ABC transporters | Aspartic acid 1;Phosphate |
References
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
Used In Evidence Reviews
Similar Papers
British journal of pharmacology · 2006
GABA and glycine as neurotransmitters: a brief history.
Human mutation · 2009
A balanced chromosomal translocation disrupting ARHGEF9 is associated with epilepsy, anxiety, aggression, and mental retardation.
Electronic physician · 2017
A review of effective herbal medicines in controlling menopausal symptoms.
Sleep medicine reviews · 2017
Not a single but multiple populations of GABAergic neurons control sleep.
Nutritional neuroscience · 2008
Suppressive effect of Yokukansan on excessive release of glutamate and aspartate in the hippocampus of zinc-deficient rats.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2018